Michelina Plateroti

Dr. Michelina Plateroti

Cancer Research Center of Lyon, UMR Inserm 1052 - CNRS 5286 – CLB, 28 rue Laennec, 69373 Lyon, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
APAnna Pasto
Anna Pasto
Valentina SerafinValentina Serafin
Valentina Serafin
GPGiorgia Pilotto
Giorgia Pilotto
CLClaudia Lago
Claudia Lago
CBChiara Bellio
Chiara Bellio
Stefano IndraccoloStefano Indraccolo
Stefano Indraccolo
MUSASHI-1 (MSI-1) is a well-established stem cell marker in both normal and malignant colon cells and it acts by positively regulating the NOTCH pathway through inactivation of NUMB, a NOTCH signaling repressor. To date, the mechanisms of regulation of MSI-1 levels remain largely unknown. Here, we investigated the regulation of MSI-1 by NOTCH signaling in colorectal cancer cell lines and in primary cultures of colorectal cancer metastases. Stimulation by the NOTCH ligand DLL4 was associated with an increase of MSI-1 mRNA and protein levels, and this phenomenon was prevented by the addition of an antibody neutralizing NOTCH2/3 but not NOTCH1. Moreover, forced expression of activated NOTCH3 increased MSI-1 levels, whereas silencing of NOTCH3 by short hairpin RNA reduced MSI-1 levels in both colorectal cancer cells and CRC tumor xenografts. Consistent with these findings, enforced NOTCH3 expression or stimulation by DLL4 increased levels of activated NOTCH1 in colorectal cell lines. Finally, treatment of colorectal cancer cells with anti-NOTCH2/3 antibody increased NUMB protein while significantly reducing formation of tumor cell spheroids. This novel feed-forward circuit involving DLL4, NOTCH3, MSI-1, NUMB, and NOTCH1 may be relevant for regulation of NOTCH signaling in physiologic processes as well as in tumor development. With regard to therapeutic implications, NOTCH3-specific drugs could represent a valuable strategy to limit NOTCH signaling in the context of colorectal cancers overexpressing this receptor. Cancer Res; 74(7); 2106–18. ©2014 AACR.

1 February 2017 in Developmental Biology
Verified
Journal Article
Closed access
SSSeham Skah
Seham Skah
JUJoel Uchuya-Castillo
Joel Uchuya-Castillo
Sirakov MariaSirakov Maria
Sirakov Maria
Michelina PlaterotiMichelina Plateroti
Michelina Plateroti

15 August 2015 in Development
Verified
Journal Article
Closed access
PDF file
Sirakov MariaSirakov Maria
Sirakov Maria
ABAmina Boussouar
Amina Boussouar
EKElsa Kress
Elsa Kress
CFCarla Frau
Carla Frau
ILImtiaz Nisar Lone
Imtiaz Nisar Lone
Michelina PlaterotiMichelina Plateroti
Michelina Plateroti
Thyroid hormones control various aspects of gut development and homeostasis. The best-known example is in gastrointestinal tract remodeling during amphibian metamorphosis. It is well documented that these hormones act via the TR nuclear receptors, which are hormone-modulated transcription factors. Several studies have shown that thyroid hormones regulate the expression of several genes in the Notch signaling pathway, indicating a possible means by which they participate in the control of gut physiology. However, the mechanisms and biological significance of this control have remained unexplored. Using multiple in vivo and in vitro approaches, we show that thyroid hormones positively regulate Notch activity through the TRα1 receptor. From a molecular point of view, TRα1 indirectly controls Notch1, Dll1, Dll4 and Hes1 expression but acts as a direct transcriptional regulator of the Jag1 gene by binding to a responsive element in the Jag1 promoter. Our findings show that the TRα1 nuclear receptor plays a key role in intestinal crypt progenitor/stem cell biology by controlling the Notch pathway and hence the balance between cell proliferation and cell differentiation.

1 December 2017 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
CFCarla Frau
Carla Frau
MGMatthias Godart
Matthias Godart
Michelina PlaterotiMichelina Plateroti
Michelina Plateroti

7 March 2014 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Sirakov MariaSirakov Maria
Sirakov Maria
EKElsa Kress
Elsa Kress
JNJulien Nadjar
Julien Nadjar
Michelina PlaterotiMichelina Plateroti
Michelina Plateroti

26 September 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
FCF.M. Cambuli
F.M. Cambuli
BCB.R. Correa
B.R. Correa
ARA. Rezza
A. Rezza
SBS.C. Burns
S.C. Burns
MQM. Qiao
M. Qiao
Michelina PlaterotiMichelina Plateroti
Michelina Plateroti
The intestinal epithelium is very peculiar for its continuous cell renewal, fuelled by multipotent stem cells localized within the crypts of Lieberkühn. Several lines of evidence have established the evolutionary conserved RNA-binding protein Musashi1 as a marker of adult stem cells, including those of the intestinal epithelium, and revealed its roles in stem cell self-renewal and cell fate determination. Previous studies from our laboratories have shown that Musashi1 controls stem cell-like features in medulloblastoma, glioblastoma, and breast cancer cells, and has pro-proliferative and pro-tumorigenic properties in intestinal epithelial progenitor cells in vitro. To undertake a detailed study of Musashi1's function in the intestinal epithelium in vivo, we have generated a mouse model, referred to as v-Msi, overexpressing Musashi1 specifically in the entire intestinal epithelium. Compared with wild type litters, v-Msi1 mice exhibited increased intestinal crypt size accompanied by enhanced proliferation. Comparative transcriptomics by RNA-seq revealed Musashi1's association with gut stem cell signature, cell cycle, DNA replication, and drug metabolism. Finally, we identified and validated three novel mRNA targets that are stabilized by Musashi1, Ccnd1 (Cyclin D1), Cdk6, and Sox4. In conclusion, the targeted expression of Musashi1 in the intestinal epithelium in vivo increases the cell proliferation rate and strongly suggests its action on stem cells activity. This is due to the modulation of a complex network of gene functions and pathways including drug metabolism, cell cycle, and DNA synthesis and repair. Stem Cells 2015;33:3621–3634